Contineum Therapeutics Statistics
Total Valuation
CTNM has a market cap or net worth of $340.83 million. The enterprise value is $102.61 million.
Important Dates
The last earnings date was Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CTNM has 39.27 million shares outstanding. The number of shares has increased by 36.25% in one year.
| Current Share Class | 35.35M |
| Shares Outstanding | 39.27M |
| Shares Change (YoY) | +36.25% |
| Shares Change (QoQ) | +2.46% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 79.01% |
| Float | 30.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 31.11, with a Debt / Equity ratio of 0.03.
| Current Ratio | 31.11 |
| Quick Ratio | 30.45 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.80% and return on invested capital (ROIC) is -20.68%.
| Return on Equity (ROE) | -29.80% |
| Return on Assets (ROA) | -28.34% |
| Return on Invested Capital (ROIC) | -20.68% |
| Return on Capital Employed (ROCE) | -29.09% |
| Weighted Average Cost of Capital (WACC) | 9.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.17% in the last 52 weeks. The beta is 1.07, so CTNM's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | -30.17% |
| 50-Day Moving Average | 10.66 |
| 200-Day Moving Average | 13.27 |
| Relative Strength Index (RSI) | 38.98 |
| Average Volume (20 Days) | 403,290 |
Short Selling Information
The latest short interest is 3.70 million, so 9.41% of the outstanding shares have been sold short.
| Short Interest | 3.70M |
| Short Previous Month | 3.66M |
| Short % of Shares Out | 9.41% |
| Short % of Float | 12.27% |
| Short Ratio (days to cover) | 2.82 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -72.41M |
| Pretax Income | -63.46M |
| Net Income | -63.46M |
| EBITDA | -72.03M |
| EBIT | -72.41M |
| Earnings Per Share (EPS) | -$1.76 |
Full Income Statement Balance Sheet
The company has $244.48 million in cash and $6.27 million in debt, with a net cash position of $238.22 million or $6.07 per share.
| Cash & Cash Equivalents | 244.48M |
| Total Debt | 6.27M |
| Net Cash | 238.22M |
| Net Cash Per Share | $6.07 |
| Equity (Book Value) | 245.42M |
| Book Value Per Share | 6.25 |
| Working Capital | 241.72M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$51.87 million and capital expenditures -$360,000, giving a free cash flow of -$52.23 million.
| Operating Cash Flow | -51.87M |
| Capital Expenditures | -360,000 |
| Depreciation & Amortization | 383,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -52.23M |
| FCF Per Share | -$1.33 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CTNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.25% |
| Shareholder Yield | -36.25% |
| Earnings Yield | -20.29% |
| FCF Yield | -15.32% |
Analyst Forecast
The average price target for CTNM is $21.43, which is 146.89% higher than the current price. The consensus rating is "Buy".
| Price Target | $21.43 |
| Price Target Difference | 146.89% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |